Loading...

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Published
08 Aug 24
Updated
04 Sep 25
AnalystConsensusTarget's Fair Value
US$347.14
12.7% undervalued intrinsic discount
10 Sep
US$303.08
Loading
1Y
-7.9%
7D
0.9%

Author's Valuation

US$347.1

12.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Sep 25
Fair value Decreased 0.88%

With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.

Shared on07 May 25
Fair value Decreased 9.45%

Shared on30 Apr 25
Fair value Decreased 0.49%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 0.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 2.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 1.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 3.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.